A Randomised Phase III Study of the duration of the Anti-PD1 - therapy in metastatic melanoma (STOP-GAP) [ 2018 - ]

Research Grant

Researchers: A/Pr Victoria Atkinson (Principal investigator) ,  Dr Janet Dancey ,  Dr Matteo Carlino ,  Dr Serigne Lo ,  Prof Madeleine King
View all 6 related researchers

Brief description PD-1 inhibitors turn on the immune system,so that it can fight the cancer cells in the body and are effective in Melanoma. This study investigates whether interrupted PD-1 inhibitor dosing has no worse Melanoma outcome than continuous treatment for 24 months, which may lead to a reduction in treatment-related toxicities, improvements in patients' quality of life and decrease the cost of treatment to the health system as well as individual. Results may inform treatments for other common cancers.

Funding Amount $2,276,727.00

Funding Scheme Project Grants

Notes Standard Project Grant